



Universiteit
Leiden

The Netherlands

From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice

Tan, Z.

Citation


Tan, Z. (2026, March 31). *From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice*. Retrieved from <https://hdl.handle.net/1887/4299937>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4299937>

Note: To cite this publication please use the final published version (if applicable).



Acknowledgements

Like many others, completing a PhD has been an important journey. The years I spent in the Netherlands pursuing my doctoral studies were truly transformative, shaping not only my pharmacometrics skills but also my outlook on life. I have emerged from this experience as a more mature researcher and individual, and none of this would have been possible without the support of many wonderful people.

First and foremost, I would like to express my deepest gratitude to my promotor team: Catherijne, Swantje, and Dirk Jan. I feel extremely fortunate to have been supervised by such a passionate and dedicated team. Your shared enthusiasm for improving clinical practice through pharmacometrics modelling has been a constant source of motivation and inspiration throughout my PhD. In particular, I am sincerely grateful to Catherijne for your comprehensive support, thoughtful guidance, and countless insightful discussions. Your extensive knowledge and impressive organisational skills, even amid a busy schedule, have made a deep impression on me and significantly influenced how I approach research and my daily life. I am deeply grateful to Dirk Jan for meticulously supporting every detail of my projects. Your strong sense of responsibility, kindness, and professionalism as both a clinician and researcher are qualities I truly admire and aspire to follow. I also wish to thank Swantje for your consistent support, prompt feedback, and practical solutions to the challenges I encountered along the way. Your patience, encouragement, and passion for life have been truly inspiring. Collectively, I thank my promotors for their guidance, patience, and unwavering support throughout my PhD.

I would also like to express my gratitude to the postdoctoral researchers who mentored me throughout this journey. Anyue offered invaluable support during my initial two projects and provided comprehensive guidance when I needed it most. Aymara contributed vital insights to my research and manuscripts, greatly enhancing their quality. I have learned so much from both of you, and I sincerely appreciate your generosity and mentorship.

Research is ultimately a team effort, and I have been fortunate to collaborate with many outstanding colleagues. I would like to thank Amy Rieborn, Hans Gelderblom, Tom van der Hulle, Jan Gerard Maring, Sofía Peeters, Thomas Manten, Maarten Deenen, Pierre Bet, Ron Mathôt, Elise Smolders, Elianne de Boer, Helle-Brit Fiebrich-Westra, Erik Metscher, Yuri van der Burgt, Jan Willem de Groot, and Peter Plomp for their valuable contributions and support. Working with you has reminded me that, without collaboration and practical implementation, pharmacometrics would remain a purely theoretical exercise. I am grateful for the opportunity to work alongside you and for the ways you


helped bring our research to life.

I would also like to acknowledge my colleagues in the Quantitative Clinical Pharmacology group, Elke, Lu, Aline, Tan, Yunjiao, Anne, Maria, and Bas for cultivating a supportive and stimulating work environment. In addition, I thank my colleagues, Henok, Qinglian, Yan, Qi, and Amar, as well as everyone at KFT for making me feel at home even as an external PhD student. Although I cannot mention everyone individually, I am truly grateful to all those at both SPP (LACDR) and KFT (LUMC) who supported me throughout this journey.

I have also been fortunate to forge many wonderful friendships at SPP. Ming has been a loyal friend, and I appreciate his consistent kindness. Thank you, Maria, for always being attentive to my emotional moments and always treated us with amazing Maltese food. My three seniors, Lu, Tan, and Yunjiao, share a similar training background in China, which led us to end up in the same group; a connection that feels like a special destiny. I greatly respect Yuchen for her extensive knowledge, from whom I have always learned a great deal and we enjoyed an unforgettable journey at UPSS. The times spent with Massi, watching movies, playing video games, and enjoying stand-up comedy, have created unforgettable memories. Chenyu generously shared his life experiences and wisdom, offering me valuable lessons both academically and personally. Thank you Yinru for not only being my “workstation successor” but also an awesome travel buddy. Last but not least, as a talented young professional, Tingjie always offered insightful advice and helped deepen my understanding of pharmacometrics and its industry.

Outside of work, I have been blessed with friends who have enriched my life in the Netherlands. Kudos to the friends in LIACS: Shuaiqun (Daniel) and his wife, Jingfen, as well as Rui, Yumeng, Jujia, Jiawen and Qianru. The laughter and joy we shared will remain with me always, and I sincerely hope we share more memories together in the near future.

Last but not least, I owe my deepest gratitude to my parents for their unconditional love and unwavering support. Your encouragement has been my foundation throughout this entire journey, and none of this would have been possible without you.



Curriculum Vitae

List of publications

CURRICULUM VITAE

Zhiyuan Tan (1995, Jiangsu, China) started his academic journey from September 2013, studying in a Bachelor of Science program in Pharmaceutical Science at Zhengzhou University in China. After his undergraduate studies, Zhiyuan pursued his M. Pharm (clinical pharmacy) program at Peking University Third Hospital in September 2017, working under the supervision of Prof. Rongsheng Zhao and Dr. Wei Liu from Department of Pharmacy and Dr. Kai Hu from Department of Hematology. During this period, he provided evidence-based pharmacy practice and therapeutic drug monitoring services to routine clinical practice. He completed his Master training in 2020 with honors.

From July 2020 to July 2021, Zhiyuan worked as PK/PD analyst at a clinical contract research organization to further expose himself in early clinical trials and PK/PD modeling.

In September 2021, Zhiyuan moved to The Netherlands and started his PhD on a collaborative project between the Leiden Academic Center for Drug Research (LACDR) and the Leiden University Medical Center, under the supervision of Prof. dr. C.A.J. Knibbe, Dr. S. Völler and Dr. D.J.A.R. Moes. His PhD projects were aimed at closing the dosing gap between oncology clinical trials and routine clinical practice by different modeling approaches.

Currently, Zhiyuan is pushing the needle from oncology to critically ill children, and also from PK/PD modeling to more mechanistic based modeling at Gent Precision Dosing Unit and Gent University Hospital.

LIST OF PUBLICATIONS

Tan Z, Smolders E, de Boer ECS, Fiebrich-Westra HB, Metscher E, van der Burgt YEM, Rieborn A, de Groot JWB, Plomp PMJ, Sancho-Araiz A, Völler S, Knibbe CAJ, Maring JG, Moes DJAR. Characterization of real-world pembrolizumab population pharmacokinetics in cancer patients: towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval. *In preparation*.

Tan Z, Sancho-Araiz A, Völler S, Peeters SLJ, Manten T, Deenen MJ, Maring JG, Bet PM, Mathôt RAA, Knibbe CAJ, Moes DJAR. Advancing precision dosing of 5-FU: Population PK model development, limited sampling strategies and fit-for-use application. *In revision*.

Tan Z, Völler S, Sancho-Araiz A, Knibbe CAJ, Moes DJAR. A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS Perspective. *J Clin Pharmacol*. 2025 Oct;65(10):1187-1207.

Tan Z, Völler S, Yin A, Rieborn A, Gelderblom H, van der Hulle T, Knibbe CAJ, Moes DJAR. Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer. *Clin Pharmacokinet*. 2025 May;64(5):715-728.

Tan Z, Völler S, Yin A, Rieborn A, Gelderblom H, van der Hulle T, Knibbe CAJ, Moes DJAR. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens. *Clin Pharmacokinet*. 2024 Jun;63(6):857-869.